Pfizer Inc. (NYSE:PFE) Shares Purchased by Richard C. Young & CO. LTD.

Richard C. Young & CO. LTD. increased its position in Pfizer Inc. (NYSE:PFE) by 2.9% in the 3rd quarter, Holdings Channel.com reports. The firm owned 452,007 shares of the biopharmaceutical company’s stock after buying an additional 12,818 shares during the quarter. Richard C. Young & CO. LTD.’s holdings in Pfizer were worth $13,081,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Pfizer in the 1st quarter valued at about $315,000. Edgestream Partners L.P. acquired a new stake in shares of Pfizer during the 1st quarter valued at approximately $243,000. Hillsdale Investment Management Inc. lifted its stake in Pfizer by 111.3% during the first quarter. Hillsdale Investment Management Inc. now owns 3,132 shares of the biopharmaceutical company’s stock worth $87,000 after purchasing an additional 1,650 shares during the last quarter. Rockport Wealth LLC acquired a new position in Pfizer in the first quarter worth $294,000. Finally, O Shaughnessy Asset Management LLC raised its holdings in shares of Pfizer by 7.1% during the first quarter. O Shaughnessy Asset Management LLC now owns 317,495 shares of the biopharmaceutical company’s stock worth $8,810,000 after purchasing an additional 20,950 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 4.7 %

Shares of NYSE PFE opened at $24.80 on Monday. The firm has a market capitalization of $140.54 billion, a PE ratio of 33.51, a PEG ratio of 0.79 and a beta of 0.67. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business has a 50-day moving average price of $28.64 and a two-hundred day moving average price of $28.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same period last year, the company earned ($0.17) earnings per share. As a group, analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.77%. Pfizer’s payout ratio is 227.03%.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on PFE shares. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Wells Fargo & Company lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Citigroup initiated coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, five have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.